title: Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.
abstract: Pancreatic cancer remains one of the most lethal and poorly understood human malignancies and will continue to be a major unsolved health problem in the 21(st) century. Despite efforts over the past three decades to improve diagnosis and treatment, the prognosis for patients with pancreatic cancer is extremely poor with or without treatment, and incidence rates are virtually identical to mortality rates. Although advances have been made through the identification of relevant molecular pathways in pancreatic cancer, there is still a critical, unmet need for the translation of these findings into effective therapeutic strategies that could reduce the intrinsic drug resistance of this disease and for the integration of these molecularly targeted agents into established combination chemotherapy and radiotherapy regimens in order to improve patients' survival. Tumors are heterogeneous cellular entities whose growth and progression depend on reciprocal interactions between genetically altered neoplastic cells and a non-neoplastic microenvironment. To date, most of the mechanisms of resistance studied have been related to tumor cell-autonomous signaling pathways. However, recent data suggest a putative important role of tumor microenvironment in the development and maintenance of resistance to classic chemotherapeutic and targeted therapies. This present review is meant to describe and discuss some of the most important advances in the comprehension of the tumor cell-autonomous and tumor microenvironment-related molecular mechanisms responsible for the resistance of pancreatic cancer to the proapoptotic activity of the classic chemotherapeutic agents and to the most novel anti-angiogenic drugs. We present some of the emerging therapeutic targets for the modulation of this resistant phenotype.
authors: Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, Università degli studi di Verona Verona, Italy.
authors: Anna
authors: A
authors: Tamburrino
authors: Geny
authors: G
authors: Piro
authors: Carmine
authors: C
authors: Carbone
authors: Giampaolo
authors: G
authors: Tortora
authors: Davide
authors: D
authors: Melisi
keywords: NF-κB; TAK-1; anti-angiogenic therapy; drug resistance; pancreatic cancer
references: J Clin Oncol. 2007 Jun 20;25(18):2607-15
references: 17577041
references: Science. 2011 Mar 25;331(6024):1612-6
references: 21436454
references: Cancer Res. 2008 Feb 1;68(3):918-26
references: 18245495
references: JAMA. 2010 Sep 8;304(10):1073-81
references: 20823433
references: Blood. 1996 Mar 15;87(6):2095-147
references: 8630372
references: Expert Opin Ther Targets. 2011 Oct;15(10):1183-96
references: 21819318
references: Curr Drug Targets. 2012 Jun;13(6):729-30
references: 22458518
references: PLoS Med. 2010 Apr 20;7(4):e1000267
references: 20422030
references: J Clin Oncol. 2005 Nov 1;23(31):8033-40
references: 16258101
references: Trends Pharmacol Sci. 2012 Oct;33(10):522-30
references: 22795313
references: J Clin Oncol. 2009 May 1;27(13):2231-7
references: 19307500
references: Cancer Cell. 2009 Mar 3;15(3):167-70
references: 19249675
references: Br J Cancer. 2007 Aug 20;97(4):523-30
references: 17622249
references: Clin Cancer Res. 2011 Sep 1;17(17):5822-32
references: 21737511
references: J Clin Oncol. 2010 Aug 1;28(22):3617-22
references: 20606091
references: Nat Rev Cancer. 2008 Aug;8(8):579-91
references: 18596824
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Curr Pharm Des. 2004;10(1):11-26
references: 14754402
references: Nature. 2012 Jul 26;487(7408):500-4
references: 22763439
references: Pancreas. 2002 Aug;25(2):122-9
references: 12142733
references: J Pathol. 2012 Aug;227(4):417-30
references: 22611036
references: Cancer Metastasis Rev. 2006 Sep;25(3):387-408
references: 17043764
references: Science. 2009 Jun 12;324(5933):1457-61
references: 19460966
references: Nat Biotechnol. 2007 Aug;25(8):911-20
references: 17664940
references: Mol Cancer Res. 2009 May;7(5):624-33
references: 19435817
references: Science. 2013 Jan 18;339(6117):286-91
references: 23329041
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Oncogene. 2002 Sep 19;21(42):6510-9
references: 12226754
references: N Engl J Med. 2011 May 12;364(19):1817-25
references: 21561347
references: Nat Rev Cancer. 2004 Oct;4(10):806-13
references: 15510161
references: Nat Rev Cancer. 2008 Aug;8(8):592-603
references: 18650835
references: J Natl Cancer Inst. 2011 Aug 3;103(15):1190-204
references: 21743023
references: Cancer Cell. 2012 Mar 20;21(3):418-29
references: 22439937
references: Cancer Treat Rev. 2009 Apr;35(2):167-74
references: 19027240
references: Nat Rev Clin Oncol. 2011 Mar 01;8(4):210-21
references: 21364524
references: Clin Cancer Res. 2004 Jan 15;10(2):784-93
references: 14760102
references: Cancer Res. 2008 Apr 1;68(7):2085-93
references: 18381413
references: Nat Immunol. 2011 Jul 19;12(8):715-23
references: 21772280
references: Expert Opin Ther Targets. 2007 Feb;11(2):133-44
references: 17227230
references: Cancer Res. 2005 Apr 15;65(8):3218-25
references: 15833853
references: Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):454-67
references: 22710569
references: Gut. 2013 Sep;62(9):1244-5
references: 23263524
references: J Biol Chem. 2004 Apr 16;279(16):16452-62
references: 14679213
references: J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
references: 17895480
references: Cancer Cell. 2012 Jan 17;21(1):105-20
references: 22264792
references: Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S1-10
references: 22443181
references: Clin Cancer Res. 1999 Jan;5(1):119-27
references: 9918209
references: Clin Cancer Res. 2012 Aug 15;18(16):4266-76
references: 22896693
references: Curr Drug Targets. 2012 Jun;13(6):795-801
references: 22458526
references: Oncogene. 2003 May 22;22(21):3243-51
references: 12761494
references: Cancer. 2000 May 15;88(10):2239-45
references: 10820344
references: Gut. 2013 Jan;62(1):112-20
references: 22466618
references: Oncogene. 2001 Feb 15;20(7):859-68
references: 11314019
references: Nat Rev Cancer. 2008 Aug;8(8):618-31
references: 18633355